MRK — Recent News Coverage
All news mentioning MRK in ESEN's AI-graded feed
News stories with MRK as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on MRK. See /coverage/MRK for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-03
HIGH
BULLISH
CORR0.72
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript
$MRK
◈ ESEN AI
Merck (MRK) presented Phase III HIV program data at an international AIDS conference, signaling meaningful clinical progress in a therapeutic area with substantial market opportunity and high regulatory visibility. Phas…
SEEKINGALPHA.COM
·
2026-08-03
NEUTRAL
NEUTRAL
CORR0.35
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference - Slideshow (NYSE:MRK) 2026-08-03
$MRK
◈ ESEN AI
Merck (MRK) presented HIV program updates and Phase III clinical data at an international AIDS conference, providing transparency on its pipeline advancement in antiretroviral therapeutics. The disclosure of trial resul…
MANILATIMES.NET
·
2026-07-30
NEUTRAL
BULLISH
CORR0.42
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
$MRK
$6990.HK
◈ ESEN AI
Sichuan Kelun-Biotech announced regulatory acceptance of a new indication application for sacituzumab tirumotecan (sac-TMT/SKB264), a TROP2-directed antibody-drug conjugate co-developed with Merck, in China's NMPA revie…
SEEKINGALPHA.COM
·
2026-07-26
LOW
NEUTRAL
CORR0.15
Analyst Connect July 2026: Portfolio Strategy Guidelines
$GNTX
$IDXX
$APP
$MRK
$DE
◈ ESEN AI
This article presents a meta-analysis of portfolio strategy frameworks compiled from institutional investor perspectives, rather than actionable market catalysts. The piece synthesizes best practices across diversified …
INSIDERMONKEY.COM
·
2026-07-23
HIGH
BULLISH
CORR0.72
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
$NVS
$LLY
$MRK
$PFE
◈ ESEN AI
Biotech M&A activity has doubled year-over-year, with deal value reaching $216 billion through current 2026 data versus $118 billion in the prior-year period. This acceleration signals heightened strategic consolidation…
SEEKINGALPHA.COM
·
2026-07-17
NEUTRAL
BULLISH
CORR0.58
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK)
$MRK
◈ ESEN AI
Merck (MRK) has received analyst attention following FDA approval of Lipfendra, a new oncology asset, coupled with ongoing pipeline advancement in cancer therapeutics. The approval represents incremental revenue diversi…
SEEKINGALPHA
·
2026-07-17
HIGH
BULLISH
CORR0.72
Personalis is said to have attracted takeover interest from Merck
$PSNL
$MRK
◈ ESEN AI
Personalis has reportedly attracted takeover interest from pharmaceutical giant Merck, representing a potential consolidation move within the precision medicine and genomics space. This development signals strategic app…
ETFTRENDS.COM
·
2026-07-17
NEUTRAL
BULLISH
CORR0.58
Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
$LLY
$UNH
$MRK
◈ ESEN AI
Health care equities demonstrated positive momentum this week, with a focus on large-cap pharmaceutical and managed care operators. The article highlights LLY, UNH, and MRK as beneficiaries of favorable sector tailwinds…
FINANCE.YAHOO.COM
·
2026-07-15
HIGH
BULLISH
CORR0.72
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
$PFE
$MRK
◈ ESEN AI
Pfizer secured a significant FDA approval milestone for PADCEV combined with Keytruda in muscle-invasive bladder cancer (MIBC), a competitive oncology market segment. This regulatory achievement represents a major catal…
FINANCE.YAHOO.COM
·
2026-07-09
LOW
NEUTRAL
CORR0.42
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
$VHT
$PPH
$JNJ
$MRK
◈ ESEN AI
VHT and PPH represent divergent approaches to healthcare exposure, with the former prioritizing breadth and the latter emphasizing pharmaceutical concentration. The comparison highlights a fundamental portfolio construc…
ZACKS.COM
·
2026-07-08
NEUTRAL
NEUTRAL
CORR0.35
Top Research Reports for Tesla, Bank of America & Merck
$TSLA
$BAC
$MRK
◈ ESEN AI
This research roundup aggregates analyst commentary on three systematically important equities: Tesla, Bank of America, and Merck. The compilation format—centering on multiple stocks across disparate sectors—suggests a …
FINANCE.YAHOO.COM
·
2026-07-04
LOW
NEUTRAL
CORR0.35
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
$ABBV
$ABT
$MRK
◈ ESEN AI
This comparative analysis examines two pharmaceutical sector ETFs—VanEck PPH and Invesco PJP—highlighting structural differences in their approach to capturing pharma opportunity. The article focuses on portfolio constr…
SEEKINGALPHA.COM
·
2026-06-29
NEUTRAL
BEARISH
CORR0.15
Crescent Biopharma: Intriguing Developer Of ADC / PD1-VEGF Assets May Not Be Sufficiently Derisked (NASDAQ:CBIO)
$CBIO
$MRK
◈ ESEN AI
Crescent Biopharma (CBIO) faces significant clinical and commercial derisking challenges as it pursues CR-001, a PD-1 x VEGF bispecific antibody intended to compete in the crowded immuno-oncology space. The implicit the…
FINANCE.YAHOO.COM
·
2026-06-26
HIGH
BULLISH
CORR0.72
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
$TECH
$MRK
◈ ESEN AI
Bio-Techne (TECH) represents a marquee acquisition in life sciences infrastructure, signaling accelerating strategic consolidation among large-cap pharma and diagnostics players. The $11.3 billion valuation reflects rob…
MANILATIMES.NET
·
2026-06-24
NEUTRAL
BULLISH
CORR0.42
Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region
$MRK
◈ ESEN AI
MRK has secured a strategic partnership with Abu Dhabi's Department of Health to explore a regional logistics hub within the HELM Cluster. This collaboration signals expansion into Middle Eastern healthcare infrastructu…
FOXBUSINESS.COM
·
2026-06-23
NEUTRAL
NEUTRAL
CORR0.35
US shoulders disproportionate cost of new medications, report finds
$JNJ
$PFE
$MRK
◈ ESEN AI
A new Office of Health Policy report quantifies a structural reality in global pharmaceutical markets: U.S. consumers bear an outsized financial burden, accounting for nearly 80% of innovative drug revenue from medicati…
SEEKINGALPHA.COM
·
2026-06-22
HIGH
BULLISH
CORR0.72
Merck’s Oncology Engine Is Still Accelerating (NYSE:MRK)
$MRK
◈ ESEN AI
Merck's FDA approval of a Keytruda combination therapy for kidney cancer represents a significant expansion of its oncology franchise, a cornerstone of the company's revenue growth strategy. This regulatory milestone va…
FINANCE.YAHOO.COM
·
2026-06-22
NEUTRAL
BULLISH
CORR0.52
Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise
$MRK
◈ ESEN AI
Merck's FDA approval for KEYTRUDA and WELIREG combination therapy in kidney cancer represents an incremental expansion of its oncology portfolio rather than a transformative development. The dual-indication approval—now…
SEEKINGALPHA.COM
·
2026-06-21
NEUTRAL
NEUTRAL
CORR0.15
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
$MRNA
$MRK
$JNJ
$BIIB
$LLY
◈ ESEN AI
Healthcare equities displayed divergent momentum this week as Moderna (MRNA) rallied while the broader Health Care Select Sector ETF (XLV) declined. The sector's mixed performance reflects competing macro and regulatory…
INSIDERMONKEY.COM
·
2026-06-19
LOW
NEUTRAL
CORR0.45
Kevin O’leary’s Stock Portfolio: Top 10 Stock Picks for 2026
$MRK
◈ ESEN AI
Kevin O'Leary's portfolio philosophy centers on cash generation and disciplined capital allocation rather than speculative growth positioning. This framework reflects a preference for mature, operationally efficient bus…
FINANCE.YAHOO.COM
·
2026-06-17
NEUTRAL
BULLISH
CORR0.42
Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now
$MRK
◈ ESEN AI
Merck has been identified as a counter-cyclical equity opportunity, with valuation positioning suggesting defensive appeal during potential market headwinds. The company's recent FDA approval milestone for KEYTRUDA in c…
SEEKINGALPHA.COM
·
2026-06-16
LOW
BULLISH
CORR0.35
Merck: Buy The Dip On This Dividend Growth Pharma Leader (NYSE:MRK)
$MRK
◈ ESEN AI
Merck (MRK) is presented as a tactical entry point at $114.90, offering a 3% dividend yield and trading at a 12x forward earnings multiple. This valuation proposition suggests the stock has experienced recent weakness, …
SEEKINGALPHA
·
2026-06-11
HIGH
BULLISH
CORR0.72
Merck Animal Health to buy biodevice developer TARGAN
$MRK
◈ ESEN AI
Merck's Animal Health division acquisition of TARGAN, a biodevice developer, signals strategic portfolio expansion within the companion and livestock health markets. M&A activity of this scale typically reflects managem…
BUSINESSWIRE
·
2026-06-11
NEUTRAL
NEUTRAL
CORR0.35
Merck Animal Health to Acquire TARGAN
$MRK
◈ ESEN AI
Merck & Co. (MRK) announced a definitive acquisition agreement for TARGAN, a private biodevice developer focused on poultry performance optimization. This move represents vertical integration within the animal health se…
EXPLORE OTHER FILTERS